Digitate Accelerates Momentum as an Industry Leader in the AIOps Market
Digitate, a SaaS-based, leading provider of autonomous enterprise solutions, today announced its recognition as a market and category leader in AIOps by multiple leading analyst firms and industry reports. Digitate earned these merits as a result of its high customer ratings and wide breadth of solutions that span across IT and business operations, as well as assurance.
Digitate’s flagship product ignio™ is an end-to-end autonomous solution that uses advanced machine learning and AI capabilities to bring contextual intelligence to IT operations. ignio™ enables enterprises with a one-of-a-kind closed-loop solution that combines context, insights and intelligent automation to autonomously predict, prevent and prescribe for issues. Digitate is helping Fortune 500 companies harness the power of AI and automation as they scale to meet the demands of their own customers and ease the ever-increasing workload on IT teams.
"Our growth over the past few years speaks to the strength of our solutions in supporting our customers' goals for digital transformation success,” said Akhilesh Tripathi, CEO of Digitate. “Digitate is committed to providing customers an AI-driven, closed-loop platform that further improves productivity, business continuity, and customer experience. Our recognition as a market leader by several prominent analyst and industry reports is a validation of our investments and the adoption of our solutions across some of the world’s leading enterprises”
Digitate’s success is highlighted by several notable achievements and recognition in 2021, including:
- Named a leader in the Omdia “AIOps Universe – Selecting an AIOps Solution 2021 - 2022” Report – Due in part to its strong automation capabilities and management control, Digitate was recognized for its commitment to creating value for business functions through automation and comprehensive AIOps capabilities. Digitate was the leader in the overall customer experience with a recommendation score of 96%. To support Digitate’s all-rounder status, it scored 95% for solution breadth.
- Recognized on the Constellation Research ShortList™ for Using Artificial Intelligence in IT Operations (AIOps) Q3 2021 – Constellation’s list evaluated over 40 most prominent AIOps solutions based on client inquiries, partner conversations, customer references, vendor selection projects, market share and internal research. Digitate was selected based on its noise reduction and enterprise capabilities, among other criteria.
- Recognized as a technology leader in Quadrant Knowledge Solution’s SPARKS Matrix for Artificial Intelligence for IT Operations (AIOps) Platform 2021 Report –The report pointed out some of the key differentiators that include Digitate’s over 10 000 out-of-the-box automation capabilities and unique, closed-loop system ensuring better ROI and lower time to value.
- Highlighted in the IDC Worldwide IT Operations Analytics Software Market Shares Report – Digitate was the second fastest-growing IT Operations Analytics software company for 2020, with a revenue growth rate of 43.5%. (August 2021, IDC #US48125121)
- Highlighted in the IDC Worldwide Workload Management Software Market Shares Report – Digitate was the fastest growing WLM software company for 2020 with a revenue growth rate of 75.6 %. (July 2021, IDC #US48063321)
About Digitate
Digitate is a leading software provider bringing agility, assurance, and resiliency to IT and business operations. Digitate’s flagship product ignio™ is an award-winning AIOps software that reimagines enterprise IT and business landscape with its unique and innovative closed-loop approach by combining context, insights and intelligent automation to autonomously resolve and prevent issues. Our customers span across industry verticals and include large, global enterprises that are leaders and innovators in their respective industries. Digitate is headquartered in Santa Clara, California, USA and Pune, India. To stay up to date on ignio™ news and to learn more how our clients across the globe have benefited from our innovative solutions: Visit us at www.digitate.com, and follow Digitate on Twitter and LinkedIn.
Learn more about our AIOps solution here: http://www.youtube.com/watch?v=xy3FGkbZNDM
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005225/en/
Contact information
Colin Rinehart
Senior Account Executive
10Fold/Digitate
digitate@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release
IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom